Prevention of aromatase inhibitor–induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer
Authors' conclusion
This real-life study confirmed that antiresorptive treatment significantly increases femoral and lumbar BMD regardless of the baseline BMD in postmenopausal patients receiving AIs for early breast cancer. Patients who did not receive antiresorptive treatment had a 20.8-fold increased risk of major bone loss.
Study context
- Population
- Postmenopausal women with estrogen receptor-positive early breast cancer receiving aromatase inhibitors (AIs)328 referred
- Participants
- 168 women
- Exposure
- Antiresorptive treatment vs no antiresorptive treatment during AI therapy
- Antiresorptive treatmentn = 144
- Outcome
- Changes in femoral and lumbar BMD
- Follow-up
- 24 months
Methodological detailslongitudinal, real-life setting, 2-year follow-up
- Longitudinal
- Real-life setting
- 2-year follow-up
Main finding
As reported in the abstract
Change in BMD
| Group | Value | Femoral-BMD (F-BMD) change | Lumbar-BMD (L-BMD) change |
|---|---|---|---|
| Antiresorptive treatment | + 6.28% | + 6.28% | + 7.79% |
Antiresorptive treatment
Value+ 6.28%
Femoral-BMD (F-BMD) change+ 6.28%
Lumbar-BMD (L-BMD) change+ 7.79%
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Major femoral bone loss (multivariate logistic model) · 24 monthsOnly predictive factor | 20.83 (4.2–100) | P < 0.001 | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Prevention of aromatase inhibitor–induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer. Osteoporos Int. Published 30 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →